Back to Search
Start Over
Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).
- Source :
-
Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2019 Aug; Vol. 19 (4), pp. 491-501. Date of Electronic Publication: 2018 Nov 19. - Publication Year :
- 2019
-
Abstract
- Background :Metastatic RCC (mRCC) treatment has been revolutionized with 11 approved targeted agents. We report patterns of practice, outcomes and pharmacoeconomic analyses after the introduction of targeted therapy. Patients and methods : CRISIS was a retrospective multicenter study of mRCCpatients who received targeted therapy . Results were related to the start of 1st-line therapy, with a cut off at 1 January 2011 in order to depict the impact of increased availability of effective options. Results : 164 patients, were included. 70.1% and 44.5% received 2nd and 3rd-line therapy, respectively. More patients were treated in 2nd-line after 1 January 2011. After a median follow-up of 55.1 months, median progression-free (PFS) and overall survival (OS) were 10.7 (95% confidence intervals [CI]: 8.3-13.7), 7.3 (95% CI: 5.1-8.6), 5.8 (95% CI: 3.8-7.8) and 34 (95% CI: 28.5-39.8), 22.4 (95% CI: 16-32.1), 18.3 (95% CI: 12.4-26.4) months for first, second and third line, respectively. Efficacy of sunitinib and pazopanib in 1st-line were similar. The mean total cost/patient was 35,012.2 Euros (standard deviation [SD]: 28,971.5). Conclusions : Our study confirms previous real-world data suggesting that continuing advances in the treatment of mRCC produce favorable outcomes in everyday practice. Pharmacoeconomic analyses are important for cost-effective utilization of emerging novel therapies.
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Agents administration & dosage
Antineoplastic Agents economics
Carcinoma, Renal Cell economics
Cost-Benefit Analysis
Disease-Free Survival
Female
Follow-Up Studies
Greece
Humans
Indazoles
Kidney Neoplasms economics
Male
Middle Aged
Molecular Targeted Therapy economics
Neoplasm Metastasis
Practice Patterns, Physicians' statistics & numerical data
Pyrimidines administration & dosage
Pyrimidines economics
Retrospective Studies
Sulfonamides administration & dosage
Sulfonamides economics
Sunitinib administration & dosage
Sunitinib economics
Survival Rate
Carcinoma, Renal Cell drug therapy
Economics, Pharmaceutical
Kidney Neoplasms drug therapy
Molecular Targeted Therapy methods
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8379
- Volume :
- 19
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Expert review of pharmacoeconomics & outcomes research
- Publication Type :
- Academic Journal
- Accession number :
- 30417707
- Full Text :
- https://doi.org/10.1080/14737167.2019.1546121